A frozen vial, a lifesaving diagnosis: how a Nova Scotia company reimagined bleeding tests and changed outcomes worldwide. In this episode of New Wave we unpack how Precision Biologic turned a simple customer insight - freeze the reagent - into a global shift in hemostasis diagnostics.

Episode breakdown & timestamps

- 00:00 Hook & scene: the everyday miracle of blood clotting and why it matters. (00:00)

- 01:48 Show intro & mission: New Wave, Life Sciences Nova Scotia & Snack Labs. (01:48)

- 02:07 The clotting cascade explained: Dr. John Geske walks us through the 13-step process and why each factor matters for diagnosis. (02:07)

- 06:55 Athlete story: Alex Dowsett on living with severe hemophilia A and the stakes of timely testing. (06:55)

- 12:10 Diagnostic delays and family stories: why unreliable tests cost years of life and peace of mind. (12:10)

- 13:48 The breakthrough: Precision Biologic’s frozen (cryopreserved) reagent strategy and product story. (13:48)

- 17:31 Cold chain & scale: liquid nitrogen, dry ice, logistics and global distribution challenges. (17:31)

- 19:31 Systems impact: how accurate diagnostics reduce costly treatment errors and protect health budgets. (19:31)

- 22:00 Closing: regulation, persistence, and what comes next for diagnostics innovation. (22:00)

Guests & bios

- Dr. John Geske — Chief Scientific Officer, Precision Biologic. He explains the science behind hemostasis, the technical hurdles for reagents, and why frozen plasma-based controls changed lab workflows.

- Paul Empy — CEO, Precision Biologic. Describes customer discovery, product strategy, and the company’s operational choices.

- Alex Dowsett — Professional cyclist and person living with severe hemophilia A. His story humanizes diagnostic urgency.

Key takeaways & memorable quotes

- "A frozen vial of plasma" became the phrase that reminded the company of the lives their work touches.

- Frozen liquid reagents eliminate a high-risk, error-prone reconstitution step in labs—improving accuracy, speed, and patient safety.

- Accurate diagnostics lower system-wide costs (avoiding unnecessary $10,000 drug switches) and speed correct treatments.

- Quote: "If you do this work once under perfect conditions and ship it frozen, you remove human error at the bench."

Why this matters

This episode explores diagnostic innovation, frozen reagents, hemostasis labs, hemophilia diagnostics, cold-chain logistics, and patient-centered product design. Target keywords include frozen diagnostics, hemophilia testing, precision biologic, cryo reagents, and Nova Scotia life sciences.

Call-to-action

If you found this episode illuminating, subscribe to New Wave, rate & review on Apple Podcasts or Spotify, and share with colleagues in lab medicine.

Links & resources mentioned

- Precision Biologic: https://precisionbiologic.com

- Life Sciences Nova Scotia: https://lifesciencesnovascotia.ca/

- Snack Labs podcast production: https://wearesnack.io

- World Federation of Hemophilia (patient resources): https://www.wfh.org

Show branding & social handles

New Wave — stories about life sciences and health tech from Nova Scotia.

Follow: Life Sciences Nova Scotia (LinkedIn) | @snackpodcasts (instagram | Precision BioLogic (LinkedIn)

This episode blends investigative reporting with scientific explanation and patient stories to reveal how a small operational change—freezing reagents—reduced diagnostic risk and improved outcomes worldwide. Perfect for clinicians, lab directors, biotech founders, and anyone interested in relatable science and systems-level healthcare impact.

Hosted on Acast. See acast.com/privacy for more information.